BioAtla, Inc

BioAtla, Inc. engages in the development of novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its CAB portfolio include MABs & ADCS, BA3011, and BA3021. The company was founded by Jay M. Short and Carolyn Anderson in March 2007 and is headquartered in San Diego, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

BioAtla reports positive trial results and financial stability in Q4

BioAtla's Q4 2022 earnings call highlighted positive trial results, strong financial position, and progress in clinical development efforts
While facing challenges such as increased R&D expenses and enrollment hurdles, the company remains focused on innovation and patient safety
Opportunities lie in leveraging dosing regimens for enhanced efficacy, responding to patient needs, and updating stakeholders on future advancements

BioAtla reports positive clinical responses and solid financial position

BioAtla showcased strong clinical progress in Phase 2 trials, with positive responses in various cancer indications. Despite financial losses, the company maintains a solid cash position. Challenges lie in optimizing dosing and balancing characteristics in combination therapies, while opportunities exist in furthering combination therapy research and FDA interactions.

BioAtla reports progress in novel cancer therapies and financial stability

BioAtla is making significant strides in developing novel therapies for solid tumor types with high unmet medical needs.
The company's financial position is stable with plans to fund operations into 2025 and explore strategic partnerships.
Challenges include managing R&D expenses, rolling out liquid biopsy to other indications, and optimizing combination therapy approaches.
Opportunities lie in potential corporate development, strategic partnerships, and expanding treatment options with promising combination therapies.

BioAtla reports positive clinical trial results and strong financial position

BioAtla showcased promising clinical trial results for BA3011 and BA3021, with a focus on delivering innovative therapies for cancer treatment. Despite increased expenses and a net loss in Q3 2023, the company maintains a strong financial position and aims to maximize shareholder value through strategic collaborations and advancements in its pipeline.

BioAtla reports strong clinical progress and financial review in Q4

BioAtla's Q4 2023 earnings call highlighted substantial progress in clinical programs, financial performance, and strategic plans for future growth.
The company's focus on advancing CAB programs, innovative therapies, and collaborations underscores its commitment to driving clinical and commercial success.
While facing challenges in regulatory processes and trial execution, BioAtla remains well-positioned to leverage opportunities for market expansion and therapeutic innovation.

BioAtla reports positive clinical data and financial progress in Q1 2024 earnings call

BioAtla's Q1 2024 Earnings Call showcased positive clinical data, financial improvements, and strategic advancements in its pipeline.
The company's focus on safety, enthusiasm from leadership, and plans for future trials indicate a promising outlook for its drug development programs.
While facing challenges in differentiation, safety management, and financial sustainability, BioAtla remains poised to capitalize on market opportunities and collaborations.

BioAtla reports robust Q3 earnings with promising oncology pipeline progress

BioAtla's Q3 2024 earnings call highlighted strong financial performance and significant advancements in their oncology pipeline, supported by positive clinical data and regulatory feedback.
The company's focus on key compounds like ozuriftamab vedotin and evalstotug in various cancer types positions them well for future growth and potential commercial success.
While challenges in clinical trial execution and regulatory complexities exist, BioAtla has opportunities to capitalize on FDA support, expand indications, and drive innovation in precision oncology.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

– Mecbotamab vedotin (BA3011) sarcoma Phase 2 top-line interim data support advancing with UPS and osteosarcoma –

BioAtla Reports First Quarter 2022 Financial Results and Highlights Recent Progress

SAN DIEGO, April 08, 2022 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody and other protein therapeutics, today announced that it plans to host a conference call and webcast on Wednesday, May 4, 2022 at 4:30 p.m. Eastern Time to discuss its financial results for the quarter ended March 31, 2022, and provide an interim topline data update from the mecbotamab vedotin (BA3011) Phase 2 study in sarcoma as well as an operational update on our ongoing clinical programs, including BA3011, ozuriftamab vedotin (BA3021) and CAB-CTLA-4 (BA3071).

BioAtla to Announce First Quarter 2022 Financial Results and Provide Business Highlights on May 4, 2022

SAN DIEGO, March 1, 2022 /PRNewswire/ -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics, today announces its financial results for the fourth quarter and full year December 31, 2021, and provides an update on product pipeline developments. "BioAtla made significant progress in 2021 by advancing the potentially registration-enabling Phase 2 clinical trials for our two lead CAB product candidates as well as our other preclinical and pipeline programs.

BIOATLA ANNOUNCES FOURTH QUARTER AND FULL YEAR 2021 FINANCIAL RESULTS

Bristol-Myers

SAN DIEGO, Jan. 10, 2022 /PRNewswire/ -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics, today announced that it has entered into a clinical collaboration with Bristol Myers Squibb (NYSE: BMY) to investigate BioAtla's two lead CAB-ADC candidates, BA3011 and BA3021, in combination with Bristol Myers Squibb's anti-PD-1 therapy Opdivo® (nivolumab).  Under the terms of the agreement, BioAtla and Bristol Myers Squibb will collaborate on clinical trials of separate combination therapies using two of BioAtla's Conditionally Active Biologic Antibody Drug Conjugates, BA3011 and BA3021, each in combination with Opdvio.

BioAtla Announces Clinical Collaboration with Bristol Myers Squibb to Study Mecbotamab Vedotin (BA3011) and Ozuriftamab Vedotin (BA3021) in Combination with Opdivo® (nivolumab) for Treatment of Solid Tumors

SAN DIEGO, Dec. 21, 2021 /PRNewswire/ -- BioAtla, Inc., a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics, today announced that Edward L. (Eddie) Williams has been appointed to the BioAtla Board of Directors and has agreed to serve on the Audit Committee of the Board.

BIOATLA APPOINTS EDWARD L. WILLIAMS TO BOARD OF DIRECTORS

SAN DIEGO, Nov. 15, 2021 /PRNewswire/ -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics, today announced financial results for the third quarter of 2021 and provided an update on its clinical progress and business. "BioAtla continues to advance the progress of the potentially registration-enabling Phase 2 clinical trials for our two lead CAB product candidates as well as our other preclinical and pipeline programs.

BioAtla Announces Third Quarter 2021 Financial Results And Provides Clinical And Business Update

SAN DIEGO, Sept. 29, 2021 /PRNewswire/ -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics, today announced that it has entered into stock purchase agreements with a group of institutional investors in connection with a private placement of its common stock.

BioAtla Announces Private Placement of 2.7 Million Shares

SAN DIEGO, Aug. 13, 2021 /PRNewswire/ -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics, today announced financial results for the second quarter of 2021 and provided an update on its business. "BioAtla is advancing potentially registration-enabling Phase 2 clinical trials for our two lead CAB product candidates.

BioAtla Announces Second Quarter 2021 Financial Results And Provides Clinical Update

SAN DIEGO, May 12, 2021 /PRNewswire/ -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics, today announced financial results for the first quarter of 2021 and provided an update on its business. "BioAtla is rapidly advancing potentially registration-enabling Phase 2 clinical trials for our two lead CAB product candidates.

BioAtla Announces First Quarter 2021 Financial Results And Provides Business Update

BioAtla is developing selectively-targeting antibodies based on very interesting science. However, it is a new IPO, and current prices and cash reserves are not conducive to investment.

BioAtla: Intriguing Science, New IPO, A Name To Watch

SAN DIEGO, Jan. 8, 2021 /PRNewswire/ -- BioAtla, Inc., a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics, today announced that Jay M. Short, Ph.D., Chief Executive Officer, and Scott Smith, President, with...

BioAtla to Present at 39th Annual J.P. Morgan Virtual Healthcare Conference

Foot Locker

GameStop

NetApp

Arvinas Inc

Coupa Software

Eos Energy Enterprises

Guidewire Software

Jack Henry & Associates

Mustang Bio

Odonate Therapeutics

Upstart Holdings

Vistra Energy

Conventional wisdom says that insiders and 10% owners really only buy shares of a company for one reason — they believe the stock price will rise and they want to profit from it. So insider buying can be an encouraging signal for potential investors, particularly when there is uncertainty in the markets, as there has been due to the pandemic resurgence and political issues.

Notable Insider Buys In The Week Of Christmas: Foot Locker, GameStop, NetApp And More

SAN DIEGO, Dec. 18, 2020 /PRNewswire/ -- BioAtla, Inc. (Nasdaq: BCAB), a clinical-stage biopharmaceutical company developing a novel class of highly specific and selective antibody-based therapeutics for the treatment of solid tumor cancer, today announced the closing of its initial...

BioAtla Announces Closing of Initial Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares

SAN DIEGO, Dec. 15, 2020 /PRNewswire/ -- BioAtla, Inc. (Nasdaq: BCAB), a clinical-stage biopharmaceutical company developing a novel class of highly specific and selective antibody-based therapeutics for the treatment of solid tumor cancer, today announced the pricing of its initial...

BioAtla Announces Pricing of Initial Public Offering

News for BioAtla, Inc Stock (BCAB)